迈威生物：调整回购价格上限至48元/股

Core Viewpoint - Maiwei Bio announced a significant adjustment to its share repurchase plan, increasing the maximum repurchase price from 35.00 yuan to 48.00 yuan per share in response to recent stock price increases and market changes [1] Group 1: Share Repurchase Plan - The company initially planned to repurchase shares at a price not exceeding 35.00 yuan per share for an amount between 25 million to 50 million yuan [1] - As of July 31, the repurchase plan had not been implemented, prompting the board to convene on August 5 to revise the plan [1] - The adjusted repurchase price is expected to allow for the acquisition of approximately 520,000 to 1,040,000 shares, representing 0.13% to 0.26% of the total share capital [1] Group 2: Regulatory Issues - The company's chairman and general manager, Liu Datao, received an administrative penalty from the Shanghai Regulatory Bureau of the China Securities Regulatory Commission for suspected short-term trading [1] - Liu was issued a warning and fined 600,000 yuan as part of the regulatory action [1]